ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Ventus Therapeutics, one of C&EN’s 10 Start-Ups to Watch in 2020, has raised $100 million in series B financing to develop small molecules that act on tough-to-drug targets in the innate immune system. Ventus says its second-most-advanced program is a molecule that targets NLRP3, an inflammasome protein implicated in a long list of diseases. The start-up has not disclosed its other programs but says it is interested in autoimmune, inflammation, oncology, and neurology indications.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter